Apnimed to Present Review of Recent Data on Investigational Pharmacologic Treatment for Obstructive Sleep Apnea at World Sleep 2023
October 18, 2023 08:00 ET
|
Apnimed, Inc.
CAMBRIDGE, Mass., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea...
Apnimed to Participate in Upcoming October Investor Conferences
October 11, 2023 08:00 ET
|
Apnimed, Inc.
CAMBRIDGE, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep...
American Journal of Respiratory and Critical Care Medicine Publishes Full, Positive Results of Apnimed’s MARIPOSA Study on AD109, an Investigational Oral Drug for Obstructive Sleep Apnea
October 10, 2023 08:30 ET
|
Apnimed, Inc.
CAMBRIDGE, Mass., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep...
Apnimed Adds Independent Director Paul Fonteyne, MS, MBA to Board of Directors
October 02, 2023 08:00 ET
|
Apnimed, Inc.
Apnimed Adds Independent Director Paul Fonteyne, MS, MBA to Board of Directors
Global Sleep Apnea Diagnostic System Industry Research Report 2023-2030 - AI Innovations Transform Sleep Disorder Diagnosis in Booming Market
September 28, 2023 10:28 ET
|
Research and Markets
Dublin, Sept. 28, 2023 (GLOBE NEWSWIRE) -- The "Sleep Apnea Diagnostic System Market, By Product Type, By End User, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030"...
Apnimed Announces First Patient Dosed in LunAIRo, the First Phase 3 Clinical Study of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea
September 21, 2023 05:30 ET
|
Apnimed, Inc.
-- LunAIRo Compares AD109 to Placebo Over 6 and 12 Months in People with OSA who Are Intolerant of or Refuse Positive Airway Pressure (PAP) Therapy, the Current Standard of Care -- -- Second...
Non-invasive Ventilators Market to Grow at a CAGR of 5.9% during the 2022 to 2031 Forecast Period: TMR Study
July 26, 2023 09:00 ET
|
Transparency Market Research
Wilmington, Delaware, United States, July 26, 2023 (GLOBE NEWSWIRE) -- The global non-invasive ventilators market stood at US$ 2.2 billion in 2022 and the global market is projected to reach US$ 3.9...
ProSomnus Announces Second Quarter 2023 Investor Call and Business Update
July 06, 2023 08:29 ET
|
ProSomnus Sleep Technologies, Inc.
PLEASANTON, Calif., July 06, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (“OSA”), will report its strong second...
ResMed Acquires Somnoware, a Leader in Digital Sleep and Respiratory Care Diagnostics Software
July 05, 2023 16:05 ET
|
ResMed Inc.
Expands ResMed’s sleep management software solution, will help sleep labs and physicians more efficiently guide patients into and through diagnosis to long-term treatmentDiagnostic management platform...
PAP Adherence Lowers ER Visits 24-36% in 1 Year for People with Sleep Apnea and Heart Failure: ResMed Studies Presented at SLEEP
June 08, 2023 09:00 ET
|
ResMed Inc.
The studies also showed 18-40% lower costs incurred from ER visits and hospitalizations after 1 year for PAP-adherent OSA patients with diastolic and systolic heart failure, respectivelyA third study...